CEO since 2015

Andreas Gerward, MSc, born 1988

Andreas has during the last 8 years worked with pharmaceutical development in smaller companies. Since joining Stayble as the CEO in 2014 Andreas has developed the company from selection of the candidate drug through preclinical development and successful clinical trials. Andreas has an engineering background and a master’s in Entrepreneurship and Business Design from Chalmers University of Technology.

Holding in the Company: 400 000 shares

Chief Scientific Officer since 2015

Anders Lehmann, PhD, born 1957

Anders has broad experience in drug development from AstraZeneca with an international network, and experience from start-ups and spin-outs. Anders is an excellent project manager for preclinical and clinical development projects. Anders holds a PhD in Neurobiology and has a background in Drug Discovery research.

Holding in the Company: 90 000 shares

CFO since 2018

Thomas Pålsson, MSc, born 1952

Thomas Pålsson has 20 years’ experience of biotech. Previous experience including Chief Financial Officer (CFO) Arexis AB, later merged with Biovitrum, Business Controller Albireo Group, a spin-out from AstraZeneca 2008 and since 2016 listed on Nasdaq New York. Thomas has a MBA from School of Economics and Business, Gothenburg University.

Holding in the Company: 106 700 shares